TP53 and non-Hodgkin lymphoma: In Non-Hodgkin Lymphoma (NHL) patients, TP53 mutation is a well-established prognostic biomarker that correlates with a higher rate of drug resistance (56% vs 17%), shorter progression-free survival (2.1 vs 8.2 months), and shorter overall survival (11.7 vs 21.5 months) for patients receiving the EPOCH therapeutic regimen (11).